share_log

Panbela Therapeutics | DEFA14A: Others

Panbela Therapeutics | DEFA14A: Others

Panbela Therapeutics | DEFA14A:其他
美股sec公告 ·  04/25 16:42
Moomoo AI 已提取核心信息
On April 23, 2024, Panbela Therapeutics, Inc. entered into a material definitive agreement with Michael T. Cullen, the Chairman of the Board of Directors. The agreement involved the sale of one share of Series A Preferred Stock to Cullen for $10. The transaction was completed on the same day. This Preferred Stock grants 90,000,000 votes to Cullen, solely for voting on proposals to amend the company's certificate of incorporation regarding a reverse stock split of the common stock. The Preferred Stock is non-convertible, does not entitle the holder to dividends, and has no liquidation rights. It may be redeemed at the discretion of the Board or upon stockholder approval of a reverse stock split. On April 25, 2024, Nasdaq filed a Form 25 indicating the...Show More
On April 23, 2024, Panbela Therapeutics, Inc. entered into a material definitive agreement with Michael T. Cullen, the Chairman of the Board of Directors. The agreement involved the sale of one share of Series A Preferred Stock to Cullen for $10. The transaction was completed on the same day. This Preferred Stock grants 90,000,000 votes to Cullen, solely for voting on proposals to amend the company's certificate of incorporation regarding a reverse stock split of the common stock. The Preferred Stock is non-convertible, does not entitle the holder to dividends, and has no liquidation rights. It may be redeemed at the discretion of the Board or upon stockholder approval of a reverse stock split. On April 25, 2024, Nasdaq filed a Form 25 indicating the delisting of Panbela Therapeutics' common stock, which will take effect ten days post-filing. Consequently, the company has applied to list its common stock on the CBOE's US Equity Listings Tier II and will maintain its OTCQB listing under the symbol 'PBLA' in the interim. Due to the delisting, a special meeting initially scheduled for May 3, 2024, to vote on the reverse stock split has been postponed to May 28, 2024, with a new record date set for April 24, 2024. A new proxy statement will be prepared and mailed for the rescheduled meeting.
2024 年 4 月 23 日,Panbela Therapeutics, Inc. 与董事会主席迈克尔·卡伦签订了实质性的最终协议。该协议涉及以10美元的价格向卡伦出售一股A系列优先股。该交易于当天完成。该优先股向卡伦授予了9,000,000张选票,仅用于对修改公司关于普通股反向拆分的公司注册证书的提案进行投票。优先股不可兑换,不赋予持有人分红的权利,也没有清算权。董事会可以自行决定赎回,也可以在股东批准反向股票拆分后兑换。2024年4月25日,纳斯达克提交了25号表格,表明Panbela Therapeutics的普通股已退市,该表将在申报后十天生效。因此,该公司已申请在芝加哥期权交易所的...展开全部
2024 年 4 月 23 日,Panbela Therapeutics, Inc. 与董事会主席迈克尔·卡伦签订了实质性的最终协议。该协议涉及以10美元的价格向卡伦出售一股A系列优先股。该交易于当天完成。该优先股向卡伦授予了9,000,000张选票,仅用于对修改公司关于普通股反向拆分的公司注册证书的提案进行投票。优先股不可兑换,不赋予持有人分红的权利,也没有清算权。董事会可以自行决定赎回,也可以在股东批准反向股票拆分后兑换。2024年4月25日,纳斯达克提交了25号表格,表明Panbela Therapeutics的普通股已退市,该表将在申报后十天生效。因此,该公司已申请在芝加哥期权交易所的美国股票上市二级股票上市,并将在此期间维持其OTCQB上市,股票代码为 “PBLA”。由于退市,原定于2024年5月3日举行的反向股票拆分投票的特别会议已推迟到2024年5月28日,创纪录的日期定为2024年4月24日。将为重新安排的会议准备并邮寄一份新的委托书。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息